Inside Cover: A Reversible and Selective Inhibitor of Monoacylglycerol Lipase Ameliorates Multiple Sclerosis (Angew. Chem. Int. Ed. 50/2014). Issue 50 (22nd October 2014)

• Record Type: Journal Article
• Authors: Hernández‐Torres, Gloria; Cipriano, Mariateresa; Hedén, Erika; Björklund, Emmelie; Canales, Ángeles; Zian, Debora; Feliú, Ana; Mecha, Miriam; Guaza, Carmen; Fowler, Christopher J.; Ortega‐Gutiérrez, Silvia; López‐Rodríguez, María L.
• Is Part Of: Angewandte Chemie international edition. Volume 53:Issue 50(2014)
• Page Start: 13624
• Page End: 13624
• Publication Date: 2014-10-22
• Subjects: Chemistry -- Periodicals; 540
• DOI: 10.1002/anie.201410020
• Languages: English
• ISSNs: 1433-7851

Abstract

<abstract abstract-type="graphical" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <p>The inhibition of monoacylglycerol lipase (MAGL) the enzyme responsible for the inactivation of the endocannabinoid 2‐arachidonoylglycerol, is a strategy for the treatment of multiple sclerosis. In their Communication on <ext-link ext-link-type="doi" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">page 13765 ff., </ext-link> M. L. López‐Rodríguez and co‐workers describe a potent, reversible, and selective inhibitor of MAGL that slows the clinical progression of multiple sclerosis without inducing undesirable CB₁‐mediated side effect.<boxed-text content-type="graphic" position="anchor" orientation="portrait"><graphic position="anchor" mimetype="image" xlink:href="ark:/27927/pgh2jc5kn1f" orientation="portrait" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink" /></boxed-text></p> </abstract>